Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Wireless patch could predict hidden heart rhythm disorder and prevent strokes

NCT ID NCT06600620

Knowledge-focused Sponsor: Liverpool University Hospitals NHS Foundation Trust Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused This study
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study uses a wireless patch to monitor the heart rhythms of 1,200 patients at high risk for atrial fibrillation (AF), a common heart rhythm problem that raises stroke risk. Participants are adults over 50 with certain acute conditions like heart failure or sepsis, but no known AF. The goal is to detect short AF episodes and use that data to build 'virtual twins'—computer models that could predict who will develop AF. This is an observational study, so it does not test a treatment, but it may lead to better risk prediction tools.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
wireless heart rhythm monitoring patch
What this could lead to
If successful, this could lead to better prediction tools for atrial fibrillation, helping doctors identify high-risk patients earlier and potentially prevent strokes.
What could go wrong
This is an observational study, not a treatment trial. It is currently suspended, and the results may not lead to immediate clinical changes. The prediction models need further validation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,200 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2024

Expected to finish

Aug 2028

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients admitted to hospital with a variety of medical conditions

Ages

50 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patients ≥50 years * Estimated risk of developing new episodes of AF greater than 5% * Sinus rhythm at presentation * One of the following acute conditions: * Patients admitted or referred to Critical Care (NOTE-AF ICU) * Patients admitted to hospital with acute heart failure (NOTE-AF HF) * Patients admitted to Emergency Services with sepsis or infection (NOTE-AF Sepsis) * Patients post upper gastrointestinal surgery (NOTE-AF PULSE-GI) * Patients post vascular interventions (NOTE-AF Vasc) * Patients with acute respiratory failure (NOTE-AF Resp) * Patients admitted after acute stroke (NOTE-AF stroke) Exclusion Criteria: * Atrial fibrillation or atrial flutter at the time of screening * Patients in atrial fibrillation or atrial flutter at time of preoperative assessment or admission to hospital * Paced cardiac rhythm * Inability to obtain consent * Allergy to plaster or silicone * Expected hospital stay less than 48 hours

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atrial fibrillation are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atrial fibrillation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atrial fibrillation Atrial fibrillation new onset Postoperative cardiovascular complications

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Liverpool University hospital Foundation trust

    Liverpool, United Kingdom

  • Liverpool university foundation trust

    Liverpool, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.